Nuvation Bio Inc 累计其他综合收益(亏损) : $ 0.18 (2023年12月 最新)
Nuvation Bio Inc累计其他综合收益(亏损)(Accumulated other comprehensive income (loss))的相关内容及计算方法如下:
累计其他综合收益(亏损)是不属于 留存收益 部分的损益总额。
截至2023年12月, Nuvation Bio Inc 过去一季度 的 累计其他综合收益(亏损) 为 $ 0.18。
点击上方“历史数据”快速查看Nuvation Bio Inc 累计其他综合收益(亏损)的历史走势;
点击上方“解释说明”快速查看关于Nuvation Bio Inc 累计其他综合收益(亏损)的详细说明;
点击上方“相关词条”快速查看与累计其他综合收益(亏损)相关的其他指标。
Nuvation Bio Inc 累计其他综合收益(亏损) (NUVB.WS 累计其他综合收益(亏损)) 历史数据
Nuvation Bio Inc 累计其他综合收益(亏损)的历史年度,季度/半年度走势如下:
Nuvation Bio Inc 累计其他综合收益(亏损) 年度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
累计其他综合收益(亏损) | 1.56 | -1.19 | -5.53 | 0.18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nuvation Bio Inc 累计其他综合收益(亏损) 季度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2022-09 | 2022-12 | 2023-03 | 2023-06 | 2023-09 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
累计其他综合收益(亏损) | 0.39 | -1.19 | -6.22 | -6.98 | -8.12 | -5.53 | -2.94 | -4.39 | -3.30 | 0.18 |
Nuvation Bio Inc 累计其他综合收益(亏损) (NUVB.WS 累计其他综合收益(亏损)) 解释说明
累计其他综合收益(亏损)是不属于 留存收益 部分的损益总额。
Nuvation Bio Inc 累计其他综合收益(亏损) (NUVB.WS 累计其他综合收益(亏损)) 相关词条
感谢查看价值大师中文站为您提供的Nuvation Bio Inc累计其他综合收益(亏损)的详细介绍,请点击以下链接查看与Nuvation Bio Inc累计其他综合收益(亏损)相关的其他词条:
Nuvation Bio Inc (NUVB.WS) 公司简介
一级行业:医疗保健
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).